CR2 Targeting Groups for Selective Complement Modulator Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering complement modulators lack specificity, leading to systemic effects and reduced efficacy due to non-targeted activation of the complement system, which is essential for both immune defense and inflammatory conditions.
Innovation Solution
Development of soluble compositions comprising a CR2 portion with specific amino acid substitutions that decrease binding affinity for EBV gp350 or IFNα, allowing targeted delivery of complement modulators to sites of complement activation using a construct that includes at least the first two N-terminal SCR domains of CR2, enabling selective binding to C3 proteolytic fragments and IFNα.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CR2 is used as a targeting group for delivering complement modulators, then delivery to sites of inflammation is achieved, but binding to EBV gp350 and IFNα also occurs causing non-specific effects
Solution Approach 1:
The patent applies parameter changes by mutating specific amino acid residues (R13, S15, R28, R36, K41, K57, K67, R83, R89) in the CR2 protein sequence to alter its binding parameters. These mutations selectively reduce or eliminate binding affinity for EBV gp350 and IFNα while preserving binding to C3 proteolytic fragments, thereby changing the specificity profile of CR2 for different ligands.
Solution Approach 2:
The patent applies local quality by introducing site-specific amino acid substitutions at particular residues within the CR2 protein structure. Rather than globally modifying the entire protein, localized mutations are made at specific binding interface residues to selectively modulate binding to certain ligands while maintaining binding to others, achieving differential specificity.
2Reliability
If systemic delivery of complement modulators is used, then broad coverage is achieved, but efficacy is reduced due to non-targeted activation of the complement system
Solution Approach 1:
The patent uses modified CR2 protein as an intermediary targeting group that mediates selective delivery of complement modulators to sites of inflammation. The CR2 mutations create a more selective intermediary that reduces off-target binding, thereby improving the precision of complement system modulation and reducing systemic side effects while maintaining therapeutic efficacy.
3Reliability
If wild-type CR2 is used for targeting, then binding to multiple ligands occurs, but specificity for complement fragments is reduced
Solution Approach 1:
The patent applies parameter changes by systematically mutating specific amino acid residues in CR2 to alter binding parameters for different ligand classes. The mutations (R13, S15, R28, R36, K41, K57, K67, R83, R89) are selected to differentially affect binding affinity for C3 fragments versus EBV gp350 and IFNα, thereby tuning the specificity parameter of CR2.
Solution Approach 2:
The patent applies local quality by making site-specific mutations at residues located in the binding interface regions of CR2. These localized changes selectively affect binding to specific ligand classes based on the structural and chemical properties of the mutated residues, creating differential binding characteristics for different ligands.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the specificity and efficacy of complement modulator delivery to sites of inflammation, reducing systemic side effects and improving therapeutic outcomes by ensuring precise targeting of complement activity modulation.
Implementation Method 1
CR2 binds four classes of ligands - complement component 3 (C3) proteolytic fragments iC3b, C3dg and C3d; the Epstein-Barr virus (EBV) glycoprotein gp350/220 (gp350); the low affinity IgE receptor CD23 (15, 16); and the cytokine interferon alpha (IFNα)
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided herein are compositions and methods directed to soluble proteins which can selectively deliver modulators of complement activity. Targeted delivery of these modulators is accomplished by selectively mutating particular amino acids in a targeting protein portion of the composition corresponding to at least the first two N-terminal SCR domains of CR2. Depending on the particular combination of mutations introduced into the targeting portion, a complement activity modulator can be selectively delivered to particular ligands of CR2 at sites where complement system activation or suppression is desired.